Your browser doesn't support javascript.
A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody Responses.
Liu, Bo; Yin, Ying; Liu, Yuxiao; Wang, Tiantian; Sun, Peng; Ou, Yangqin; Gong, Xin; Hou, Xuchen; Zhang, Jun; Ren, Hongguang; Luo, Shiqiang; Ke, Qian; Yao, Yongming; Xu, Junjie; Wu, Jun.
  • Liu B; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Yin Y; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Liu Y; Medical Innovation Research Division & Fourth Medical Center of the Chinese PLA General Hospital, Beijing 100853, China.
  • Wang T; Department of Neurosurgery, First Medical Center of the Chinese PLA General Hospital, Beijing 100853, China.
  • Sun P; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Ou Y; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Gong X; Shenzhen Taihe Biotechnology Co. Ltd., Shenzhen 518001, China.
  • Hou X; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Zhang J; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Ren H; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Luo S; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Ke Q; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Yao Y; Institute of Physical Science and Information Technology, Anhui University, Hefei 230000, China.
  • Xu J; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
  • Wu J; Institute of Physical Science and Information Technology, Anhui University, Hefei 230000, China.
Engineering (Beijing) ; 13: 107-115, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1306953
ABSTRACT
In 2020 and 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, caused a global pandemic. Vaccines are expected to reduce the pressure of prevention and control, and have become the most effective strategy to solve the pandemic crisis. SARS-CoV-2 infects the host by binding to the cellular receptor angiotensin converting enzyme 2 (ACE2) via the receptor-binding domain (RBD) of the surface spike (S) glycoprotein. In this study, a candidate vaccine based on a RBD recombinant subunit was prepared by means of a novel glycoengineered yeast Pichia pastoris expression system with characteristics of glycosylation modification similar to those of mammalian cells. The candidate vaccine effectively stimulated mice to produce high-titer anti-RBD specific antibody. Furthermore, the specific antibody titer and virus-neutralizing antibody (NAb) titer induced by the vaccine were increased significantly by the combination of the double adjuvants Al(OH)3 and CpG. Our results showed that the virus-NAb lasted for more than six months in mice. To summarize, we have obtained a SARS-CoV-2 vaccine based on the RBD of the S glycoprotein expressed in glycoengineered Pichia pastoris, which stimulates neutralizing and protective antibody responses. A technical route for fucose-free complex-type N-glycosylation modified recombinant subunit vaccine preparation has been established.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Engineering (Beijing) Year: 2022 Document Type: Article Affiliation country: J.eng.2021.06.012

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Engineering (Beijing) Year: 2022 Document Type: Article Affiliation country: J.eng.2021.06.012